Compounds for Induced Pluripotent Stem Cells: Products


Induced pluripotent stem (iPS) cells were first generated from fibroblasts by exogenously expressing four transcription factors: KLF4, c-Myc, Oct-4, and SOX2. However, somatic cell reprogramming can be inefficient, and the use of viral vectors can complicate their therapeutic potential. Thus, bioactive small molecules are important tools for optimizing iPS cell generation and research. Compounds such as Thiazovivin can be added to culture media to enhance the efficiency of iPS cell generation. Chromatin modifying small molecules, such as those that target histone deacetylases (HDACs) or methyltransferases, can also aid in somatic cell reprogramming by opening chromatin and promoting the transcription of pluripotency genes. In fact, following epigenetic changes induced by Valproic Acid, a HDAC inhibitor, iPS cells can be generated from somatic cells with the introduction of only Oct-4 and SOX2. Recent reports indicate that small molecules can also replace the function of particular transcription factors. For example, Kenpaullone, a Cyclin Dependent Kinase and GSK-3 beta inhibitor, can replace KLF4. Tocris provides a complete range of small molecules to optimize somatic cell reprogramming and reduce the need for viral-mediated transduction of transcription factors.

"Compounds for Induced Pluripotent Stem Cells" has 44 results in Products.
Sort by:
Results Per Page:

SB 431542 

Potent, selective inhibitor of TGF-βRI, ALK4 and ALK7

CHIR 99021 

Highly selective GSK-3 inhibitor

A 83-01 

Selective inhibitor of TGF-βRI, ALK4 and ALK7

IWP 2 

PORCN inhibitor; inhibits Wnt processing and secretion

PD 0325901 

Potent inhibitor of MEK1/2

XAV 939 

Potent tankyrase inhibitor

L-Ascorbic acid 

Enhances the generation of iPSCs; increases reprogramming efficiency


ROCK inhibitor ; improves the efficiency of fibroblast reprogramming and induction of iPSCs

3-Deazaneplanocin A hydrochloride 

EZH2 histone methyltransferase inhibitor

Valproic acid, sodium salt 

Histone deacetylase inhibitor

endo-IWR 1 

Wnt/β-catenin signaling inhibitor; axin stabilizer

LY 294002 hydrochloride 

Prototypical PI 3-kinase inhibitor; also inhibits other kinases

(±)-Bay K 8644 

CaV1.x activator


Inhibitor of Hedgehog (Hh) signaling


Potent and selective inhibitor of TGF-βRI

Trichostatin A 

Potent histone deacetylase inhibitor


Retinoic acid analog; RAR agonist

Pifithrin-α hydrobromide 

p53 inhibitor. Also aryl hydrocarbon receptor agonist


DNA methyltransferase inhibitor

Sodium butyrate 

Histone deacetylase inhibitor

Tranylcypromine hydrochloride 

Irreversible inhibitor of LSD1; also inhibits MAO

IDE 1 

Induces definitive endoderm formation in mouse and human ESCs

IDE 2 

Induces definitive endoderm formation in mouse and human ESCs

IWP 4 

Potent inhibitor of Wnt/β-catenin signaling


GSK-3β inhibitor; also inhibits cdks


Inhibitor of p53-mitochondrial binding

RG 108 

Non-nucleoside DNA methyltransferase inhibitor

BIX 01294 

GLP and G9a inhibitor

SR 3677 dihydrochloride 

Potent, selective Rho-kinase (ROCK) inhibitor

Sinomenine hydrochloride 

Anti-inflammatory; causes mast cell degranulation and histamine release

IQ 1 

Enables Wnt/β-catenin-driven expansion of ESCs; prevents spontaneous differentiation

QS 11 

ARFGAP1 inhibitor; modulates Wnt/β-catenin signaling

Cardiogenol C hydrochloride 

Induces cardiomyocyte differentiation in ESCs

Cardionogen 1 

Inhibitor of Wnt/β-catenin signaling

PluriSln 1 

SCD-1 inhibitor

Shz 1 

Activator of early cardiac genes in pluripotent stem cells; induces differentiation in M-PBMCs

CKI 7 dihydrochloride 

CK1 inhibitor


Oct3/4 inducer


Oct3/4 inducer; induces expression of pluripotent-associated genes

ID 8 

Sustains self-renewal and pluripotency of ESCs

KY 02111 

Inhibits canonical Wnt signaling. Promotes differentiation of human ESCs and iPSCs into cardiomyocytes


Oct4 activator; enhances iPSC reprogramming efficiency

SB 431542 

SB 431542 synthesized to cGMP guidelines

CHIR 99021 

CHIR 99021 synthesized to cGMP guidelines
page of 1